Biois Corp. said it would utilize the government’s “technology exception policy” to get listed on the KOSDAQ market. The company designated Mirae Asset Daewoo as the leading underwriter.
|Officials stand at the booth of Biois at the Bio Europe 2018 conference, held from Monday to Wednesday in Copenhagen, Denmark.|
The technology exception policy allows easier listing for firms with technological potentials and growth prospects, even if they do not meet the sales requirement for listing. Companies that passed the financial regulator’s assessment on technological potentials must apply for a preliminary review for KOSDAQ listing within six months.
Established in 2013, Biois developed its platform for aptamers, known as replacements for antibodies. Last year, the company received “CE marking” on nine products of AptaSign, an in-vitro diagnostic device. CE marking indicates that a product complies with European standards.
The AptaSign product for lung cancer drew keen interest and cooperation in Europe. The Korean company is actively discussing with a U.S. diagnostic firm to launch “Laboratory Developed Tests” (LDT), Biois said.
The biotech firm is participating in the Bio Europe 2018 which runs through Wednesday in Copenhagen, Denmark. The company said it would seek various cooperative efforts with multinational pharmaceuticals during the event.
Among the key topics, the company is discussing to utilize more than 100 cancer-targeting aptamers to develop an Aptamer-Drug Carrier (ApDC) and to encapsulate it. Biois’ innovative drugs can minimize the side effects of existing anticancer drugs and maximize their efficacy. The efficacy of the new drugs has been confirmed in animal tests, according to the company.
“On the back of the global interest in aptamer-based technologies and active research, we are meeting with 12 multinational pharmaceuticals including Merck, AbbVie, and Boehringer Ingelheim for partnership discussion,” an official at Biois said.
He went on to say that the company’s technological strength allowed it to offer biomarker development service, develop aptamer-based new drugs, do an encapsulation study, and provide AptaSign’s service to diagnose nine diseases (eight cancer and Lou Gehrig's disease) with CE marking.
“We will discuss more on them during the event,” he said.
For the regulator’s review of its technological potentials, Biois plans to submit data and documents including the results of partnering with European firms within the year, the company said.
<© Korea Biomedical Review, All rights reserved.>